Morning Briefing
Summaries of health policy coverage from major news organizations
Candidate Malaria Vaccine Represents 'Potentially Encouraging Anti-Malaria Strategy,' Researchers Say
A team of researchers led by Stephen Hoffman of Sanaria Inc. have created a candidate malaria vaccine against Plasmodium falciparum, the most deadly of the malaria parasites, using live but weakened parasites that "represents a potentially encouraging anti-malaria strategy," an NIH/National Institute of Allergy and Infectious Diseases press release reports. The findings of the research, which "was conducted by scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, working in concert with a large team of collaborators," were published in Thursday's online issue of Science, the press release states (9/8).
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
